There are several clinical studies showing that zidovudine treatment, in combination with interferon α (IFN-α), targets EBV in lymphoma cells [16,17] and HTLV1 in adult T-cell leukemia-lymphoma [18], leading to tumor inhibition. This evidence concerns the gene IFNA1 and lymphoma.